Evidence map›Paper›PMID 28330649›Full record

Trial reportThe lancet. Diabetes & endocrinology2017

Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.

Jelena P Seferovic, Brian Claggett, Sara B Seidelmann, Ellen W Seely, Milton Packer, Michael R Zile, Jean L Rouleau, Karl Swedberg, Martin Lefkowitz, Victor C Shi and 3 more

2 registry-linked trialsAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 160 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 6 pooled it
24.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07139405 phase2not yet recruitingstarted 2026, after this paper: background citation

A Double-Blind, Randomized, Active-Controlled Phase 2a Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of TriGlytza®-01 in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy

Ran2026Enrolled48Registered outcomes11Posted comparisons0ConditionsType 2 Diabetes (T2DM)ArmsCelecoxib, Metformin XR, valsartan
PMID 21233852other papers from this trial
Open the trial in the graph
NCT04055428 phase2recruitingnot on this mapstarted 2020, after this paper: background citation

The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals (NAUTICAL)

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2020 to 2027Enrolled200ConditionsDiabetes Mellitus, Cardiovascular Diseases, Insulin Sensitivity/Resistance, Metabolic DiseaseArmsSacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test, Standardized Meals, Exercise capacity VO2 maximum determination
3 · Its place in the literature

Who cites it

160 citing papers in PubMed, 6 syntheses or guidelines pooled it, 349 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Article
  16. Article
  17. Cardiovascular Pharmacotherapy and Glucose Metabolism: The Good, the Bad and the Unsightly.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Review
  18. Review
  19. Article
  20. Sacubitril/Valsartan-Induced Hypoglycemia After Gastric Bypass: A Case Report with Documented Endogenous Hyperinsulinemia.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article

100 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 4 countries.

Jelena P SeferovicCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Brian ClaggettCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sara B SeidelmannCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Ellen W SeelyEndocrinology, Diabetes, and Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Milton PackerBaylor University Medical Center, Dallas, TX, USA.
Michael R ZileThe Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston, SC, USA.
Jean L RouleauUniversité de Montréal, Institut de Cardiologie, Montréal, QC, Canada.
Karl SwedbergDepartment of Molecular and Clinical Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Martin LefkowitzNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Victor C ShiNovartis Pharmaceutical Corporation, East Hanover, NJ, USA.
Akshay S DesaiCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
John J V McMurrayBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: ssolomon@bwh.harvard.edu.
Brigham and Women's Hospital · USHarvard University · USNovartis (United States) · USBaylor University Medical Center · USMedical University of South Carolina · USMontreal Heart Institute · CASahlgrenska University Hospital · SEUniversity of Glasgow · GB

Funding

Noninvasive Cardiovascular Imaging Research Training ProgramT32HL094301 · BRIGHAM AND WOMEN'S HOSPITAL · 2025 to 2025
$624k
NHLBI NIH HHS R01 HL123478NHLBI NIH HHS T32 HL094301
6 · The paper itself

Abstract

backgroundDiabetes is an independent risk factor for heart failure progression. Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and improves peripheral insulin sensitivity in obese hypertensive patients. We aimed to investigate the effect of sacubitril/valsartan versus enalapril on HbA

methodsIn a post-hoc analysis of the PARADIGM-HF trial, we included 3778 patients with known diabetes or an HbA

findingsThere were no significant differences in HbA

interpretationPatients with diabetes and HFrEF enrolled in PARADIGM-HF who received sacubitril/valsartan had a greater long-term reduction in HbA

fundingNovartis.

Indexed as

AgedAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsBlood GlucoseDiabetes Mellitus, Type 2Drug CombinationsEnalaprilFemaleHeart FailureHumansMaleMiddle AgedTetrazolesValsartanAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin II Type 1 Receptor BlockersBiphenyl CompoundsBlood GlucoseDrug CombinationsEnalaprilsacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartan

Identifiers

PMID28330649
PMCPMC5534167
OpenAlexW2595010755

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.